Trials / Unknown
UnknownNCT02587689
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.
Conditions
- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
- Pancreatic Carcinoma
- Triple-Negative Invasive Breast Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-MUC1 CAR T Cells |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-10-01
- Completion
- 2018-10-01
- First posted
- 2015-10-27
- Last updated
- 2016-12-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02587689. Inclusion in this directory is not an endorsement.